{"id":"https://openalex.org/W2589173879","doi":"https://doi.org/10.1097/cmr.0000000000000350","title":"BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response","display_name":"BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response","publication_year":2017,"publication_date":"2017-02-24","ids":{"openalex":"https://openalex.org/W2589173879","doi":"https://doi.org/10.1097/cmr.0000000000000350","mag":"2589173879","pmid":"https://pubmed.ncbi.nlm.nih.gov/28240681"},"language":"en","primary_location":{"id":"doi:10.1097/cmr.0000000000000350","doi":"https://doi.org/10.1097/cmr.0000000000000350","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0000000000000350","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000719977","display_name":"C\u00e9line Desvignes","orcid":"https://orcid.org/0000-0002-5102-5908","observed_orcids":["https://orcid.org/0000-0002-5102-5908"]},"institutions":[{"id":"https://openalex.org/I4210155195","display_name":"H\u00f4pital Claude Huriez","ror":"https://ror.org/05cpv3t46","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406","https://openalex.org/I4210155195"]}],"countries":["FR"],"is_corresponding":true,"raw_author_name":"C\u00e9line Desvignes","raw_affiliation_strings":["Department of Dermatology, Lille University Hospital, Claude Huriez Hospital","fax: +3 332 044 5916"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Lille University Hospital, Claude Huriez Hospital","institution_ids":["https://openalex.org/I4210155195"]},{"raw_affiliation_string":"fax: +3 332 044 5916","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054057057","display_name":"Henry Abi Rached","orcid":"https://orcid.org/0000-0003-0419-0086","observed_orcids":["https://orcid.org/0000-0003-0419-0086"]},"institutions":[{"id":"https://openalex.org/I4210155195","display_name":"H\u00f4pital Claude Huriez","ror":"https://ror.org/05cpv3t46","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406","https://openalex.org/I4210155195"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Henry Abi Rached","raw_affiliation_strings":["Department of Dermatology, Lille University Hospital, Claude Huriez Hospital"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Lille University Hospital, Claude Huriez Hospital","institution_ids":["https://openalex.org/I4210155195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062568098","display_name":"Carole Templier","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2279609970","display_name":"Universit\u00e9 de Lille","ror":"https://ror.org/02kzqn938","country_code":"FR","type":"education","lineage":["https://openalex.org/I2279609970"]},{"id":"https://openalex.org/I4210155195","display_name":"H\u00f4pital Claude Huriez","ror":"https://ror.org/05cpv3t46","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406","https://openalex.org/I4210155195"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Carole Templier","raw_affiliation_strings":["Department of Dermatology, Lille University Hospital, Claude Huriez Hospital","Lille University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Lille University Hospital, Claude Huriez Hospital","institution_ids":["https://openalex.org/I4210155195"]},{"raw_affiliation_string":"Lille University","institution_ids":["https://openalex.org/I2279609970"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023851321","display_name":"\u00c9lodie Drumez","orcid":"https://orcid.org/0000-0003-4103-236X","observed_orcids":["https://orcid.org/0000-0003-4103-236X"]},"institutions":[{"id":"https://openalex.org/I2279609970","display_name":"Universit\u00e9 de Lille","ror":"https://ror.org/02kzqn938","country_code":"FR","type":"education","lineage":["https://openalex.org/I2279609970"]},{"id":"https://openalex.org/I3018718406","display_name":"Centre Hospitalier Universitaire de Lille","ror":"https://ror.org/02ppyfa04","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Elodie Drumez","raw_affiliation_strings":["Department of Biostatistics, Univ. Lille, CHU Lille, EA 2694 - Sant\u00e9 publique: \u00e9pid\u00e9miologie et qualit\u00e9 des soins"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics, Univ. Lille, CHU Lille, EA 2694 - Sant\u00e9 publique: \u00e9pid\u00e9miologie et qualit\u00e9 des soins","institution_ids":["https://openalex.org/I2279609970","https://openalex.org/I3018718406"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024945159","display_name":"Pauline Lepesant","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2279609970","display_name":"Universit\u00e9 de Lille","ror":"https://ror.org/02kzqn938","country_code":"FR","type":"education","lineage":["https://openalex.org/I2279609970"]},{"id":"https://openalex.org/I4210155195","display_name":"H\u00f4pital Claude Huriez","ror":"https://ror.org/05cpv3t46","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406","https://openalex.org/I4210155195"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Pauline Lepesant","raw_affiliation_strings":["Department of Dermatology, Lille University Hospital, Claude Huriez Hospital","Lille University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Lille University Hospital, Claude Huriez Hospital","institution_ids":["https://openalex.org/I4210155195"]},{"raw_affiliation_string":"Lille University","institution_ids":["https://openalex.org/I2279609970"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083267352","display_name":"Eve Desmedt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2279609970","display_name":"Universit\u00e9 de Lille","ror":"https://ror.org/02kzqn938","country_code":"FR","type":"education","lineage":["https://openalex.org/I2279609970"]},{"id":"https://openalex.org/I4210155195","display_name":"H\u00f4pital Claude Huriez","ror":"https://ror.org/05cpv3t46","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406","https://openalex.org/I4210155195"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Eve Desmedt","raw_affiliation_strings":["Department of Dermatology, Lille University Hospital, Claude Huriez Hospital","Lille University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Lille University Hospital, Claude Huriez Hospital","institution_ids":["https://openalex.org/I4210155195"]},{"raw_affiliation_string":"Lille University","institution_ids":["https://openalex.org/I2279609970"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077421764","display_name":"Laurent Mortier","orcid":"https://orcid.org/0000-0002-2644-1790","observed_orcids":["https://orcid.org/0000-0002-2644-1790"]},"institutions":[{"id":"https://openalex.org/I154526488","display_name":"Inserm","ror":"https://ror.org/02vjkv261","country_code":"FR","type":"government","lineage":["https://openalex.org/I154526488"]},{"id":"https://openalex.org/I2279609970","display_name":"Universit\u00e9 de Lille","ror":"https://ror.org/02kzqn938","country_code":"FR","type":"education","lineage":["https://openalex.org/I2279609970"]},{"id":"https://openalex.org/I4210155195","display_name":"H\u00f4pital Claude Huriez","ror":"https://ror.org/05cpv3t46","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I3018718406","https://openalex.org/I4210155195"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Laurent Mortier","raw_affiliation_strings":["Department of Dermatology, Lille University Hospital, Claude Huriez Hospital","INSERM U1189 ONCO-THAI, F-59000 Lille, France","Lille University"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Dermatology, Lille University Hospital, Claude Huriez Hospital","institution_ids":["https://openalex.org/I4210155195"]},{"raw_affiliation_string":"INSERM U1189 ONCO-THAI, F-59000 Lille, France","institution_ids":["https://openalex.org/I154526488"]},{"raw_affiliation_string":"Lille University","institution_ids":["https://openalex.org/I2279609970"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5000719977"],"corresponding_institution_ids":["https://openalex.org/I4210155195"],"apc_list":null,"apc_paid":null,"fwci":1.7535,"has_fulltext":false,"cited_by_count":29,"citation_normalized_percentile":{"value":0.84320013,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"27","issue":"3","first_page":"281","last_page":"287"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10392","display_name":"Cutaneous Melanoma Detection and Management","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/braf-inhibitors","display_name":"BRAF inhibitors","score":0.9890000224113464},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.8119999766349792},{"id":"https://openalex.org/keywords/braf-v600-mutation","display_name":"BRAF V600 mutation","score":0.9160000085830688},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.9430000185966492},{"id":"https://openalex.org/keywords/rechallenge","display_name":"drug rechallenge","score":0.7369999885559082},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.9700000286102295},{"id":"https://openalex.org/keywords/metastatic-melanoma","display_name":"metastatic melanoma","score":0.753000020980835},{"id":"https://openalex.org/keywords/recurrence","display_name":"recurrence","score":0.5239999890327454},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9829999804496765},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.6079999804496765},{"id":"https://openalex.org/keywords/immunomodulatory-antibodies","display_name":"immunomodulatory antibodies","score":0.6869999766349792}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9306707382202148},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.8032808303833008},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.638022243976593},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6255680918693542},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6182034611701965},{"id":"https://openalex.org/C3019096185","wikidata":"https://www.wikidata.org/wiki/Q1340863","display_name":"Complete response","level":3,"score":0.5969781875610352},{"id":"https://openalex.org/C2994587330","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Metastatic melanoma","level":3,"score":0.5709877014160156},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.47791630029678345},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.4288368821144104},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.41333678364753723},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4120839238166809},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.3491441011428833},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3441861867904663},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2216871976852417},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.21554774045944214},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.12475359439849854}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003131","descriptor_name":"Combined Modality Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D008545","descriptor_name":"Melanoma","qualifier_ui":"Q000601","qualifier_name":"surgery","is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009362","descriptor_name":"Neoplasm Metastasis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009364","descriptor_name":"Neoplasm Recurrence, Local","qualifier_ui":"Q000601","qualifier_name":"surgery","is_major_topic":false},{"descriptor_ui":"D011379","descriptor_name":"Prognosis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012074","descriptor_name":"Remission Induction","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015996","descriptor_name":"Survival Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016022","descriptor_name":"Case-Control Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019233","descriptor_name":"Retreatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D048493","descriptor_name":"Proto-Oncogene Proteins B-raf","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1097/cmr.0000000000000350","doi":"https://doi.org/10.1097/cmr.0000000000000350","is_oa":false,"landing_page_url":"https://doi.org/10.1097/cmr.0000000000000350","pdf_url":null,"source":{"id":"https://openalex.org/S3207524","display_name":"Melanoma Research","issn_l":"0960-8931","issn":["0960-8931","1473-5636"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma Research","raw_type":"journal-article"},{"id":"pmid:28240681","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28240681","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Melanoma research","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1513791093","https://openalex.org/W1965370740","https://openalex.org/W1978653625","https://openalex.org/W1995200019","https://openalex.org/W2004038675","https://openalex.org/W2040956995","https://openalex.org/W2052781279","https://openalex.org/W2058390096","https://openalex.org/W2099034576","https://openalex.org/W2099044540","https://openalex.org/W2102557111","https://openalex.org/W2103675014","https://openalex.org/W2125485324","https://openalex.org/W2128542677","https://openalex.org/W2160000537","https://openalex.org/W2163188200","https://openalex.org/W2163563579","https://openalex.org/W2163773590","https://openalex.org/W2166262263","https://openalex.org/W2287370367","https://openalex.org/W2398343537","https://openalex.org/W2411838582","https://openalex.org/W2529244178","https://openalex.org/W2587803040","https://openalex.org/W2588168619","https://openalex.org/W6733744192"],"related_works":["https://openalex.org/W2398343537","https://openalex.org/W2580800726","https://openalex.org/W2529244178","https://openalex.org/W4308926134","https://openalex.org/W3163826882","https://openalex.org/W3216308245","https://openalex.org/W2773413889","https://openalex.org/W7203982343","https://openalex.org/W7117146795","https://openalex.org/W4377103710"],"abstract_inverted_index":{"BRAF":[0],"inhibitors":[1],"(BRAFi),":[2],"a":[3,50,77,115,149,153,204],"targeted":[4,24,54,241],"therapy,":[5],"are":[6,38],"used":[7],"to":[8,185,189,234],"treat":[9],"metastatic":[10,69],"late-stage":[11],"melanomas":[12],"harbouring":[13],"the":[14,63,91,97,109,194],"BRAF-V600":[15],"mutation":[16],"(found":[17],"in":[18,41,101,137],"about":[19],"50%":[20],"of":[21,66,90,99,120,159,178,196,238,240],"melanomas).":[22],"The":[23,124,206,218],"therapy":[25,55,74],"is":[26,44],"generally":[27],"maintained":[28],"until":[29],"tumour":[30],"progression":[31],"or":[32],"major":[33],"toxicity":[34],"occurs,":[35],"although":[36],"responses":[37],"often":[39],"limited":[40],"time.":[42],"It":[43],"unknown":[45],"whether":[46],"melanoma":[47,70],"patients":[48,67,103,140,147,169,200,221],"achieving":[49,76],"complete":[51,78,150],"response":[52,79,85,111,173,187],"with":[53,68,82,87,152,170,175,203,232],"can":[56],"safely":[57],"discontinue":[58],"treatment.":[59],"We":[60,94],"retrospectively":[61],"observed":[62,136],"clinical":[64,236],"course":[65],"who":[71],"discontinued":[72],"BRAFi":[73,100,117,128,212],"after":[75,104,114,127,157,211],"and":[80,183,188,243],"those":[81],"an":[83,171],"incomplete":[84,172],"combined":[86,174],"surgical":[88,176],"removal":[89,177],"remaining":[92,179,220],"tumours.":[93,180],"also":[95],"evaluated":[96],"effectiveness":[98],"these":[102],"recurrence.":[105],"In":[106],"11":[107,139],"patients,":[108],"best":[110,186],"was":[112,130,135,214],"diagnosed":[113],"median":[116,125,154,207],"treatment":[118],"duration":[119],"105":[121],"(29-341)":[122],"days.":[123,133,145,217],"follow-up":[126],"initiation":[129],"769":[131],"(435-1765)":[132],"Recurrence":[134],"all":[138],"(100%),":[141],"median:":[142],"82":[143,164],"(27-322)":[144],"Five":[146],"achieved":[148],"response,":[151],"progression-free":[155,208],"survival":[156,209],"cessation":[158],"136.5":[160],"(34-322)":[161],"days":[162,166],"versus":[163],"(27-144)":[165],"for":[167],"six":[168],"Baseline":[181],"characteristics":[182],"time":[184,210],"discontinuation":[190],"did":[191],"not":[192],"influence":[193],"rate":[195],"relapse.":[197],"Subsequently,":[198],"eight":[199],"were":[201],"rechallenged":[202],"BRAFi.":[205,226],"rechallenge":[213],"222.5":[215],"(15-425)":[216],"three":[219],"received":[222],"treatments":[223],"other":[224],"than":[225],"Our":[227],"findings":[228],"may":[229],"be":[230],"valuable":[231],"respect":[233],"ongoing":[235],"trials":[237],"combinations":[239],"therapies":[242],"immunomodulatory":[244],"antibodies.":[245]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":8},{"year":2019,"cited_by_count":7},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2017-03-03T00:00:00"}